Literature DB >> 16191068

Short and long alteplase dwells in dysfunctional hemodialysis catheters.

Jennifer Marie Macrae1, Gabriel Loh, Ognjenka Djurdjev, Steven Shalansky, Ron Werb, Adeera Levin, Mercedeh Kiaii.   

Abstract

BACKGROUND: Hemodialysis catheter dysfunction (CD) is the inability to attain adequate blood pump speeds (BPS) and is attributed to thrombus or catheter malposition; alteplase (TPA) is often given in a variety of dwell times to treat CD. The purpose of this study was to determine if TPA dwell time affects short- or long-term catheter patency rates.
METHODS: Sixty hemodialysis (HD) patients with CD, as defined by BPS of < 250 mL/min, were randomized to receive either 1- or > 48-hr (to subsequent HD run) TPA dwell. The primary outcomes were catheter patency (BPS of > 250 mL/min) at the subsequent HD run and catheter patency at 2 weeks. The secondary outcome was the time from study entry to the next catheter intervention (including subsequent TPA installation).
RESULTS: After TPA installation, a 78% overall catheter patency rate was observed at the subsequent HD run, falling to 48% patency at 2 weeks. There is no statistically significant difference between the short and long TPA dwell groups for catheter patency at the subsequent HD run (76.9% vs. 79.4%) or at 2 weeks (42.3% vs. 52.9%). Multivariate analysis demonstrates that the use of TPA on two or more previous occasions is a predictor of TPA failure both at the subsequent HD run and at 2 weeks. TPA installation achieves a median catheter function time of only 14 days, after which CD reoccurs.
CONCLUSION: This study demonstrates that although patency for the next HD run can be achieved with either short or long TPA dwell, neither is reliable in terms of long-term patency. Strategies that employ TPA for CD are temporary and allow a 2-week window during which more definitive therapies for HD access should be sought.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16191068     DOI: 10.1111/j.1492-7535.2005.01131.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  8 in total

1.  Improvement of hemodialysis catheter function with tenecteplase: a phase III, open-label study: TROPICS 4.

Authors:  Steven Fishbane; Samuel L Milligan; Kenneth D Lempert; Joachim E W Hertel; James B Wetmore; Matthew J Oliver; Martha Blaney; Barbara S Gillespie; Joan R Jacobs; Susan M Begelman
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

2.  Patency and Complications of Translumbar Dialysis Catheters.

Authors:  Fanna Liu; Stacy Bennett; Susana Arrigain; Jesse Schold; Robert Heyka; Gordon McLennan; Sankar D Navaneethan
Journal:  Semin Dial       Date:  2015-03-20       Impact factor: 3.455

3.  A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3.

Authors:  James Tumlin; Jesse Goldman; David M Spiegel; David Roer; K Adu Ntoso; Martha Blaney; Joan Jacobs; Barbara S Gillespie; Susan M Begelman
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-04       Impact factor: 8.237

4.  Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).

Authors:  Jennifer M Macrae; Ivana Dojcinovic; Ognjenka Djurdjev; Beverly Jung; Steven Shalansky; Adeera Levin; Mercedeh Kiaii
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

Review 5.  Interventions for treating central venous haemodialysis catheter malfunction.

Authors:  Alice L Kennard; Giles D Walters; Simon H Jiang; Girish S Talaulikar
Journal:  Cochrane Database Syst Rev       Date:  2017-10-26

6.  Prevention of catheter lumen occlusion with rT-PA versus heparin (Pre-CLOT): study protocol of a randomized trial [ISRCTN35253449].

Authors:  Brenda R Hemmelgarn; Louise Moist; Rachel M Pilkey; Charmaine Lok; Marc Dorval; Paul Y W Tam; Murray J Berall; Martine LeBlanc; Edwin B Toffelmire; Braden J Manns; Nairne Scott-Douglas
Journal:  BMC Nephrol       Date:  2006-04-11       Impact factor: 2.388

7.  Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial.

Authors:  David R Ward; Louise M Moist; Jennifer M MacRae; Nairne Scott-Douglas; Jianguo Zhang; Marcello Tonelli; Charmaine E Lok; Steven D Soroka; Brenda R Hemmelgarn
Journal:  Can J Kidney Health Dis       Date:  2014-07-08

8.  Use of tissue plasminogen activator in catheters used for extracorporeal renal replacement therapy.

Authors:  C Langston; A Eatroff; K Poeppel
Journal:  J Vet Intern Med       Date:  2014-01-17       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.